These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 29157287)

  • 21. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Examining the Relationship between Circulating CD4- CD8- Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy-Looking for Biomarkers and Therapeutic Targets in Metastatic Melanoma.
    Strippoli S; Fanizzi A; Negri A; Quaresmini D; Nardone A; Armenio A; Sciacovelli AM; Massafra R; De Risi I; De Tullio G; Albano A; Guida M
    Cells; 2021 Feb; 10(2):. PubMed ID: 33669266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel drugs in clinical development for hepatocellular carcinoma.
    Waidmann O; Trojan J
    Expert Opin Investig Drugs; 2015; 24(8):1075-82. PubMed ID: 26108356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy for hepatocellular carcinoma.
    Li S; Yang F; Ren X
    Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer.
    O'Rourke JM; Sagar VM; Shah T; Shetty S
    World J Gastroenterol; 2018 Oct; 24(39):4436-4447. PubMed ID: 30357021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention.
    Tian M; Shi Y; Liu W; Fan J
    Sci China Life Sci; 2019 Sep; 62(9):1138-1143. PubMed ID: 31119560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?
    Ferrara R; Mezquita L; Auclin E; Chaput N; Besse B
    Cancer Treat Rev; 2017 Nov; 60():60-68. PubMed ID: 28889085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma.
    Moriguchi M; Umemura A; Itoh Y
    Clin J Gastroenterol; 2016 Aug; 9(4):184-90. PubMed ID: 27401471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ferroptosis, pyroptosis and necroptosis in hepatocellular carcinoma immunotherapy: Mechanisms and immunologic landscape (Review).
    Liu RJ; Yu XD; Yan SS; Guo ZW; Zao XB; Zhang YS
    Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
    Akbulut Z; Aru B; Aydın F; Yanıkkaya Demirel G
    Front Immunol; 2024; 15():1379622. PubMed ID: 38638433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
    Dang TO; Ogunniyi A; Barbee MS; Drilon A
    Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beyond platinum treatment for NSCLC: what does the future hold?
    Santarpia M; Karachaliou N; Rosell R
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):293-295. PubMed ID: 28129003
    [No Abstract]   [Full Text] [Related]  

  • 33. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
    Busato D; Mossenta M; Baboci L; Di Cintio F; Toffoli G; Dal Bo M
    Expert Rev Clin Pharmacol; 2019 May; 12(5):453-470. PubMed ID: 30907177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Kim HK; Heo MH; Lee HS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):591-598. PubMed ID: 28733892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of systemic treatment for advanced hepatocellular carcinoma.
    Wu TC; Shen YC; Cheng AL
    Kaohsiung J Med Sci; 2021 Aug; 37(8):643-653. PubMed ID: 34213069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.
    O'reilly A; Larkin J
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):647-655. PubMed ID: 28604130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
    Greten TF; Abou-Alfa GK; Cheng AL; Duffy AG; El-Khoueiry AB; Finn RS; Galle PR; Goyal L; He AR; Kaseb AO; Kelley RK; Lencioni R; Lujambio A; Mabry Hrones D; Pinato DJ; Sangro B; Troisi RI; Wilson Woods A; Yau T; Zhu AX; Melero I
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
    Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
    Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.